Display options
Cite
Bitzer M, Ostermann L, Horger M, et al. Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precis Oncol. 2020;4doi: 10.1200/PO.19.00359.
Bitzer, M., Ostermann, L., Horger, M., Biskup, S., Schulze, M., Ruhm, K., Hilke, F., Öner, �. �., Nikolaou, K., Schroeder, C., Riess, O., Fend, F., Zips, D., Hinterleitner, M., Zender, L., Tabatabai, G., Beha, J., & Malek, N. P. (2020). Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO precision oncology, 4. https://doi.org/10.1200/PO.19.00359
Bitzer, Michael, et al. "Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options." JCO precision oncology vol. 4 (2020). doi: https://doi.org/10.1200/PO.19.00359
Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, Malek NP. Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. JCO Precis Oncol. 2020 Mar 30;4. doi: 10.1200/PO.19.00359. eCollection 2020. PMID: 32923905; PMCID: PMC7446530.
Copy Download .nbib Format: NLM
Share it on

JCO Precis Oncol. 2020 Mar 30;4. doi: 10.1200/PO.19.00359. eCollection 2020.

Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options.

JCO precision oncology

Michael Bitzer, Leonie Ostermann, Marius Horger, Saskia Biskup, Martin Schulze, Kristina Ruhm, Franz Hilke, Öznur Öner, Konstantin Nikolaou, Christopher Schroeder, Olaf Riess, Falko Fend, Daniel Zips, Martina Hinterleitner, Lars Zender, Ghazaleh Tabatabai, Janina Beha, Nisar P Malek

Affiliations

  1. Department of Internal Medicine I, Eberhard-Karls University, Tuebingen, Germany.
  2. Cluster of Excellence, Image Guided and Functionally Instructed Tumor Therapies, Eberhard-Karls University, Tuebingen, Germany.
  3. Center for Personalized Medicine, Eberhard-Karls University, Tuebingen, Germany.
  4. Department of Diagnostic and Interventional Radiology, Eberhard-Karls University, Tuebingen, Germany.
  5. CeGaT GmbH and Praxis für Humangenetik, Tuebingen, Germany.
  6. Institute of Medical Genetics and Applied Genomics, Eberhard-Karls University, Tuebingen, Germany.
  7. Institute of Pathology and Neuropathology, Eberhard-Karls University, Tuebingen, Germany.
  8. German Cancer Research Consortium, German Cancer Research Center, Heidelberg, Germany.
  9. Department of Radiation Oncology, Eberhard-Karls University, Tuebingen, Germany.
  10. Department of Internal Medicine VIII, Eberhard-Karls University, Tuebingen, Germany.
  11. Interdisciplinary Division of Neuro-Oncology, Eberhard-Karls University, Tuebingen, Germany.

PMID: 32923905 PMCID: PMC7446530 DOI: 10.1200/PO.19.00359

Abstract

PURPOSE: Precision oncology connects highly complex diagnostic procedures with patient histories to identify individualized treatment options in interdisciplinary molecular tumor boards (MTBs). Detailed data on MTB-guided treatments and outcome with a focus on advanced GI cancers have not been reported yet.

PATIENTS AND METHODS: Next-generation sequencing of tumor and normal tissue pairs was performed between April 2016 and February 2018. After identification of relevant molecular alterations, available clinical studies or in-label, off-label, or matched experimental treatment options were recommended. Follow-up data and a response assessment that was based on radiologic imaging were recorded.

RESULTS: Ninety-six patients were presented to the MTB of Tuebingen University Hospital. Sixteen (17%) showed "pathogenic" or "likely pathogenic" germline variants. Recommendations on the basis of molecular alterations or tumor mutational burden were given for 41 patients (43%). Twenty-five received the suggested drug, and 20 were evaluable for best response assessment. Three patients (15%) reached a partial response (PR), and 6 (30%), stable disease (SD), whereas 11 (55%) had tumor progression (progressive disease). Median progression-free survival (PFS) for all treated and evaluable patients was 2.8 months (range, 1.0-9.0 months), and median overall survival (OS) of all treated patients was 5.2 months (range, 0.1 months to not reached). Patients with SD for ≥ 3 months or PR compared with progressive disease showed both a statistically significant longer median PFS (7.8 months [95% CI, 4.2 to 11.4 months]

CONCLUSION: Next-generation sequencing diagnostics of advanced GI cancers identified a substantial number of pathogenic or likely pathogenic germline variants and unique individual treatment options. Patients with PR or SD in the course of MTB-recommended treatments seemed to benefit with respect to PFS and OS.

© 2020 by American Society of Clinical Oncology.

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I

References

  1. JCO Precis Oncol. 2018 Aug 16;2: - PubMed
  2. Cancer Discov. 2017 Sep;7(9):943-962 - PubMed
  3. N Engl J Med. 2018 May 31;378(22):2093-2104 - PubMed
  4. Cell. 2018 Apr 5;173(2):355-370.e14 - PubMed
  5. JCO Precis Oncol. 2019;3: - PubMed
  6. Nature. 2015 Apr 30;520(7549):609-11 - PubMed
  7. Nat Rev Cancer. 2019 Mar;19(3):133-150 - PubMed
  8. Genet Med. 2017 Feb;19(2):249-255 - PubMed
  9. Nat Rev Cancer. 2017 Aug 24;17(9):557-569 - PubMed
  10. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  11. BMC Med Genomics. 2017 May 19;10(1):33 - PubMed
  12. Annu Rev Med. 2018 Jan 29;69:333-347 - PubMed
  13. Nat Genet. 2018 Sep;50(9):1271-1281 - PubMed
  14. Nat Med. 2019 May;25(5):744-750 - PubMed
  15. Hum Mutat. 2008 Nov;29(11):1282-91 - PubMed
  16. NPJ Genom Med. 2016 Jan 13;1:15006 - PubMed
  17. Public Health Genomics. 2017;20(2):70-80 - PubMed
  18. Nat Med. 2017 Jun;23(6):703-713 - PubMed
  19. JAMA Oncol. 2016 Jan;2(1):104-11 - PubMed
  20. Genome Med. 2017 Apr 19;9(1):34 - PubMed
  21. J Gastrointest Oncol. 2018 Aug;9(4):610-617 - PubMed
  22. Eur J Cancer. 2017 Dec;87:122-130 - PubMed
  23. Int J Cancer. 2019 Feb 15;144(4):848-858 - PubMed
  24. CA Cancer J Clin. 2016 Jan-Feb;66(1):75-88 - PubMed
  25. N Engl J Med. 2019 Oct 24;381(17):1632-1643 - PubMed
  26. Sci Transl Med. 2015 Apr 15;7(283):283ra53 - PubMed
  27. Genet Med. 2015 May;17(5):405-24 - PubMed
  28. J Clin Oncol. 2018 Mar 10;36(8):773-779 - PubMed
  29. Nat Rev Clin Oncol. 2019 Jun;16(6):386-396 - PubMed
  30. J Clin Oncol. 2015 Sep 1;33(25):2753-62 - PubMed
  31. Nature. 2019 Jul;571(7766):576-579 - PubMed
  32. N Engl J Med. 2019 Jul 25;381(4):317-327 - PubMed
  33. Cancer Sci. 2018 Mar;109(3):513-522 - PubMed
  34. N Engl J Med. 2017 Dec 21;377(25):2500-2501 - PubMed
  35. Lancet Oncol. 2017 Mar;18(3):e143-e152 - PubMed
  36. Oncotarget. 2017 Apr 18;8(16):27145-27154 - PubMed
  37. Genome Med. 2016 Jul 26;8(1):79 - PubMed
  38. J Hepatol. 2017 Jun;66(6):1166-1172 - PubMed
  39. Cancer Cell. 2018 May 14;33(5):853-861.e4 - PubMed
  40. Mol Cancer Ther. 2012 Sep;11(9):2062-71 - PubMed
  41. Nat Genet. 2019 Feb;51(2):202-206 - PubMed

Publication Types